PDG20 Availability and Affordability of Oncologic Immunotherapies across Multiple-Countries

While immunotherapies are reportedly effective without serious adverse effects, their high costs could limit their access. This study aimed to compare the access to the immunotherapy across multiple countries in terms of availability and affordability. This study targeted 7 Immune checkpoint inhibitors (Atezolizumab, Avelumab, Ipilimumab, Nivolumab, Pembrolizumab, Durvalumab, Cemiplimab) approved by US FDA as of April 2020 to compare their...